Critical Reviews in Oncogenesis最新文献_第8页

In Memory of Peter Stambrook. 纪念彼得·斯坦布鲁克。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.v27.i2.60

Bevin P Engleward

引用次数: 0

Preface: Novel Therapeutic Targets and Biomarkers in Prostate Cancer. 前言:前列腺癌的新治疗靶点和生物标志物。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043661

Lisa G Horvath, Renea A Taylor, Roger J Daly

引用次数: 0

Curcumin: The Golden Nutraceutical on the Road to Cancer Prevention and Therapeutics. A Clinical Perspective. 姜黄素:癌症预防和治疗道路上的黄金营养品。临床视角。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2023045587

Aviral Kumar, Mangala Hegde, Dey Parama, Ajaikumar B Kunnumakkara

{"title":"Curcumin: The Golden Nutraceutical on the Road to Cancer Prevention and Therapeutics. A Clinical Perspective.","authors":"Aviral Kumar, Mangala Hegde, Dey Parama, Ajaikumar B Kunnumakkara","doi":"10.1615/CritRevOncog.2023045587","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2023045587","url":null,"abstract":"Cancer is considered as the major public health scourge of the 21st century. Although remarkable strides were made for developing targeted therapeutics, these therapies suffer from lack of efficacy, high cost, and debilitating side effects. Therefore, the search for safe, highly efficacious, and affordable therapies is paramount for establishing a treatment regimen for this deadly disease. Curcumin, a known natural, bioactive, polyphenol compound from the spice turmeric (Curcuma longa), has been well documented for its wide range of pharmacological and biological activities. A plethora of literature indicates its potency as an anti-inflammatory and anti-cancer agent. Curcumin exhibits anti-neoplastic attributes via regulating a wide array of biological cascades involved in mutagenesis, proliferation, apoptosis, oncogene expression, tumorigenesis, and metastasis. Curcumin has shown a wide range of pleiotropic anti-proliferative effect in multiple cancers and is a known inhibitor of varied oncogenic elements, including nuclear factor kappa B (NF-κB), c-myc, cyclin D1, Bcl-2, VEGF, COX-2, NOS, tumor necrosis factor alpha (TNF-α), interleukins, and MMP-9. Further, curcumin targets different growth factor receptors and cell adhesion molecules involved in tumor growth and progression, making it a most promising nutraceutical for cancer therapy. To date, curcumin-based therapeutics have completed more than 50 clinical trials for cancer. Although creative experimentation is still elucidating the immense potential of curcumin, systematic validation by proper randomized clinical trials warrant its transition from lab to bedside. Therefore, this review summarizes the outcome of diverse clinical trials of curcumin in various cancer types.","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"27 3","pages":"33-63"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10034807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioactive Compounds from Curcuma amada and Their Effect on Acute Myeloid Leukemia. 姜黄生物活性成分及其对急性髓系白血病的作用。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2023047542

Ajila Chandran, Varsha Jayasankar, Paul Spagnuolo, Jayasankar Subramanian

引用次数: 0

Investigating the Anti-Cancer Properties of 6-Shogaol in Zingiber officinale. 研究人参中的 6-Shogaol 的抗癌特性。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022045100

Sowsan Hafuth, Sukhpal Randhawa

引用次数: 1

Progress in Tuberous Sclerosis Complex Renal Disease. 结节性硬化复杂肾脏疾病的研究进展。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022042857

John J Bissler, Dinah Batchelor, J Christopher Kingswood

引用次数: 1

Preface: Oral Cancer: New Insights in Diagnosis, Prognosis, Therapeutics to Management and Reconstruction. 前言:口腔癌:诊断、预后、治疗、管理和重建的新见解。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.v27.i4.40

Ragini D Singh

引用次数: 0

Immunotherapy and Targeted Therapy in the Management of Oral Cancers. 口腔癌的免疫治疗和靶向治疗。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022046361

Siddhartha Dutta, Shubha Singhal, Rima B Shah, Mainul Haque

{"title":"Immunotherapy and Targeted Therapy in the Management of Oral Cancers.","authors":"Siddhartha Dutta, Shubha Singhal, Rima B Shah, Mainul Haque","doi":"10.1615/CritRevOncog.2022046361","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022046361","url":null,"abstract":"Oral cancers (OCs), being one of the frequent malignancies in the head and neck region, need prompt diagnosis and treatment. Apart from basic therapeutic modalities, immunotherapy has now been utilized as a novel approach to combat the disease. With the comprehension of the strategies adopted by cancer cells to evade the immune elimination by the body's immune system, targeted immunotherapies have now become the core area of research. The immune expression of epidermal growth factor receptor (EGFR), programmed cell death protein ligand-1 (PDL-1), etc., are enhanced in OC and have been associated with evasion of the immune system. Targeted immunotherapies now include monoclonal antibodies targeting EGFR like cetuximab and panitumumab, programmed cell death-1 (PD-1) inhibitors like pembrolizumab, cemiplimab, and nivolumab, and PD-L1 inhibitors like atezolizumab, avelumab, and durvalumab. Targeted immunotherapies like chimeric antigen receptor T-cell treatment and small molecule inhibitors are in several clinical trials tried as monotherapy and adjuvant immunotherapy and have shown promising results. Other immunothera-peutic approaches such as cytokines like interferons or interleukins, vaccines, and gene therapy have also been an area of research for the management of OC. However, the cautious selection of appropriate patients with specific immune characteristics as a candidate for immunotherapeutic agents is a crucial component of targeted immunotherapy. This article elaborates on the immune contexture of oral cancer cells, the mechanism of immune evasion by cancer cells, targets for immunotherapies, existent immunotherapeutic agents, and prospects in the field of immunotherapy.","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"27 4","pages":"23-37"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9678857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tribute in Memory of Peter Stambrook. 纪念彼得·斯坦布鲁克。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.v27.i2.70

Benjamin Bonavida

引用次数: 0

Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs). 前列腺癌相关成纤维细胞(CAFs)的新治疗靶点和生物标志物。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043478

Kimberley C Clark, Yunjian Wu, Renea A Taylor, Roger J Daly

{"title":"Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs).","authors":"Kimberley C Clark, Yunjian Wu, Renea A Taylor, Roger J Daly","doi":"10.1615/CritRevOncog.2022043478","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022043478","url":null,"abstract":"Despite advances in treatment, prostate cancer remains a significant cause of morbidity and mortality worldwide. While the vast majority of prostate cancer research has centered on malignant epithelial cells, the tumor mi croenvironment (TME) has recently become increasingly recognized as an important regulator of tumor progression and response to treatment. Among the diverse cell types within the TME, stromal fibroblasts, in particular cancer-associated fibroblasts (CAFs), play an important role in prostate cancer progression. This is highlighted by the prognostic value of CAF markers in prostate cancer, which can predict disease recurrence, metastasis, and patient survival. There are also an increasing number of studies that demonstrate the critical role of CAFs in mediating response to specific therapies and CAF signaling pathways as potential therapeutic targets. However, further investigation into the mechanisms that underpin the interactions between cancer cells and CAFs are required to develop novel therapeutic approaches and identify predictive and prognostic biomarkers in CAFs. In this review, we discuss the current knowledge of CAF-dependent regulatory pathways in prostate tumorigenesis and their prognostic and therapeutic potential. Furthermore, we explore the emerging models and technologies that are likely to progress this field of research in terms of discovery and translation to the clinic.","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":" ","pages":"1-24"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40647574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1